Rolf Fimmers

Summary

Affiliation: Heinrich Heine University
Country: Germany

Publications

  1. ncbi Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94
    Peter Albers
    Department of Urology, Klinikum Kassel GmbH, Kassel, Germany
    J Clin Oncol 26:2966-72. 2008
  2. ncbi Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group
    Peter Albers
    Department of Urology, Bonn University, Germany
    J Urol 171:1835-8. 2004
  3. ncbi Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial
    Peter Albers
    Department of Urology, Bonn University, D 53105 Bonn, Germany
    J Clin Oncol 21:1505-12. 2003
  4. ncbi Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years
    Cordelia Luyken
    Department of Neurosurgery, University of Bonn Medical Center, Bonn, Germany
    Cancer 101:146-55. 2004
  5. ncbi The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects
    Cordelia Luyken
    Department of Neurosurgery, University of Bonn Medical Center, Bonn, Germany
    Epilepsia 44:822-30. 2003
  6. ncbi Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99)
    Günter Niegisch
    Department of Urology, Heinrich Heine University, Medical Faculty, Dusseldorf, Germany
    Eur Urol 60:1087-96. 2011
  7. ncbi Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines
    Frank G Perabo
    Department of Urology, University of Bonn, 53105 Bonn, Germany
    Anticancer Res 23:4805-14. 2003
  8. ncbi An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma
    Christian Rabe
    Department of Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 15:1305-15. 2003
  9. ncbi Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy
    Hendrik Pels
    Department of Neurology, University of Bonn, Germany
    J Clin Oncol 21:4489-95. 2003
  10. ncbi Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme
    Matthias Simon
    Department of Neurosurgery, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
    Neurosurgery 59:1078-85; discussion 1085. 2006

Collaborators

Detail Information

Publications11

  1. ncbi Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94
    Peter Albers
    Department of Urology, Klinikum Kassel GmbH, Kassel, Germany
    J Clin Oncol 26:2966-72. 2008
    ..Aim of this trial was to prove the advantage of one cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy compared with RPLND in terms of recurrence...
  2. ncbi Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group
    Peter Albers
    Department of Urology, Bonn University, Germany
    J Urol 171:1835-8. 2004
    ..We evaluated the prognostic parameters of necrotic residual tumors after chemotherapy of advanced germ cell tumors to improve on the current indications for surgery...
  3. ncbi Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial
    Peter Albers
    Department of Urology, Bonn University, D 53105 Bonn, Germany
    J Clin Oncol 21:1505-12. 2003
    ..To prospectively assess potential risk factors for relapse in clinical stage I nonseminomatous germ cell tumors of the testis (CS I NSGCT)...
  4. ncbi Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years
    Cordelia Luyken
    Department of Neurosurgery, University of Bonn Medical Center, Bonn, Germany
    Cancer 101:146-55. 2004
    ..To date, only case reports and small series of patients with short-term follow-up have been available for the assessment of the potential of GGs to recur and progress...
  5. ncbi The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects
    Cordelia Luyken
    Department of Neurosurgery, University of Bonn Medical Center, Bonn, Germany
    Epilepsia 44:822-30. 2003
    ..To describe the histologic spectrum and clinical characteristics of patients with neuroepithelial tumors and drug-resistant epilepsy and to analyze clinical data and treatment related to seizure outcome and survival...
  6. ncbi Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99)
    Günter Niegisch
    Department of Urology, Heinrich Heine University, Medical Faculty, Dusseldorf, Germany
    Eur Urol 60:1087-96. 2011
    ..In the treatment of urothelial cancer, identification of patients who are likely to benefit from further therapy after cisplatin failure is crucial for reasonable treatment decisions...
  7. ncbi Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines
    Frank G Perabo
    Department of Urology, University of Bonn, 53105 Bonn, Germany
    Anticancer Res 23:4805-14. 2003
    ..In this study, we evaluated different application schedules to determine the efficacy of the combination and its potential interactions...
  8. ncbi An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma
    Christian Rabe
    Department of Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 15:1305-15. 2003
    ..We therefore tested the ability of several newer scores to predict survival in comparison to the Okuda score in a European cohort of HCC patients...
  9. ncbi Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy
    Hendrik Pels
    Department of Neurology, University of Bonn, Germany
    J Clin Oncol 21:4489-95. 2003
    ..Response rate and response duration in this series are comparable to the response rates and durations reported after combined radiotherapy and chemotherapy. Neurotoxicity was infrequent...
  10. ncbi Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme
    Matthias Simon
    Department of Neurosurgery, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
    Neurosurgery 59:1078-85; discussion 1085. 2006
    ..Patients with LFS experience a variety of cancers, including malignant astrocytomas. We investigated a potential role for a CHEK2 gene polymorphism in glioblastomas...